TrialJournal of the American Heart Association2018

MR-proADM as a Prognostic Marker in Patients With ST-Segment-Elevation Myocardial Infarction-DANAMI-3 (a Danish Study of Optimal Acute Treatment of Patients With STEMI) Substudy.

Alexander C Falkentoft et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.